Cargando…
Comparison of Different Methods for Defining Hyperprogressive Disease in NSCLC
INTRODUCTION: Hyperprogressive disease (HPD) as a consequence of immune checkpoint inhibitors in NSCLC has been reported in multiple studies. However, inconsistent results in incidence and survival outcomes within studies, together with different assessment methods, have led to increasing controvers...
Autores principales: | Rocha, Pedro, Ramal, Didac, Ripoll, Enric, Moliner, Laura, Corbera, Alex, Hardy-Werbin, Max, Orrillo, Mayra, Taus, Álvaro, Zuccarino, Flavio, Gibert, Joan, Perera-Bel, Júlia, Casadevall, David, Arriola, Edurne |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474364/ https://www.ncbi.nlm.nih.gov/pubmed/34589976 http://dx.doi.org/10.1016/j.jtocrr.2020.100115 |
Ejemplares similares
-
Multiple Brain Pseudoprogression in a Patient With NSCLC Treated With Pembrolizumab
por: Moliner, Laura, et al.
Publicado: (2020) -
EGFR-Mutant Lung Adenocarcinoma Mimicking a Pneumonia
por: Taus, Álvaro, et al.
Publicado: (2012) -
MET Inhibitors in Small Cell Lung Cancer: From the Bench to the Bedside
por: Hardy-Werbin, Max, et al.
Publicado: (2019) -
Hyperprogressive NSCLC With Two Immune-Checkpoint Inhibitors
por: Kasparian, Saro, et al.
Publicado: (2020) -
MultiCOVID: a multi modal deep learning approach for COVID-19 diagnosis
por: Hardy-Werbin, Max, et al.
Publicado: (2023)